Event Program - University of Sydney

clattergumneckBiotechnology

Oct 23, 2013 (4 years and 16 days ago)

135 views

Biomarkers Workshop


1


EVENT PROGRAM

Event:


Biomarkers

Workshop: A discussion on finding reliable predictors of health r
isks

Date/Time:


Wednesday 9
th

November

2011, 9
.
00a
m to
2.35
pm

(registrations &

coffee from 8.30am)

Location:

New Law School Lecture Theatre 10
1
,
along Eastern Avenue, Camperdown Campus, University
of Sydney
, NSW 2006


Host:


Centre for Obesity, Diabetes and Cardiovascular Disease, the University of Sydney

ORDER OF PROCEEDINGS

8.30
-

9:00

Registration and coffee

9.00

-

9.
05

Welcome and Introductio
n given by Professor David Cook


Session 1: Current Approaches to Biomarkers
: Chairs: Len Kritharides and Tony Keech



9.05
-

9.35

Stefan
Blankenbe
rg
, Director, University Heart Centre of the University Medical Centre, Hamburg

Topic title:

Cardiovascular biomarkers


current status and future

9.
35

-

9.5
0

Peter Meikle,

Baker
IDI Heart and Diabetes

Institute

Topic title:
Lipidomics
: Application to
obesity, diabetes and cardiovascular disease

9.50

-

10.
05

Susan Clark
, Garvan Institute of Medical Research

Topic title:
Epigenome profiling

10.05

-

10.20

Rudi Grimm, Agilent Technologies

Topic title:
Glycomics

10.20

-

10.35

Karlh
einz

Peter, Baker Heart Research Institute

Topic title:
Proteomics

10.35

-

10.50

Stuart Cordwell, School of Molecular Bioscience, the University of Sydney

Topic title
:
Glycoproteomics


a critical challenge for cardiovascular research

10.
50

-

11.10

Morning
tea break

1
1.10

-

11.40

Panel Discussion

Session 2:

Strategies for Success
: Chairs: Len Kritharides and Tony Keech

11.45
-


12.00


Ian Kerridge
,

Centre for Values, Ethics and Law in Medicine,
the University of Sydney

Topic title:
Ethical issues

12.00
-

12.15

David Sullivan
,
Department of Biochemistry, Royal Prince Alfred Hospital, Sydney

Topic title:
Key infrastructure

Biomarkers Workshop


2


12.15
-

12.30


Alicia Jenkins, Department of Medicine, University of Melbourne

Topic title:
High throughput analysis

12.30
-

12.45

Claire Wade
, Faculty of Veterinary Science, The University of Sydney

Topic title:
Development of a haplotype imputation resource for the equine

12.45
-

13.00

Panel Discussion

13.00
-

13.30

Lunch


Session 3: What I want from a Biomarker Facility at
CODCD
:
Chairs: Len Kritharides and Tony Keech

13.30
-

14.00







14.00

-

14.30



Roland Stocker

Leonard Kritharides

Tony Keech

Graham Hillis

David Handelsman

Open Discussion


Discussion topics
-


Organisation of a Biomarker Facility


vir瑵al or pUyVical?

䍡paci瑹 for 䍵rren琬 New anT Novel Bio浡rkerV

14.30

䍬oVing aTTreVV fro洠In瑥rna瑩onal Speaker



S瑥fan Blankenberg











Biomarkers Workshop


3


OPENING

Professor David Cook, Academic Director, Centre for Obesity, Diabetes and Cardiovascular
Disease
, The University of
Sydney


David Cook is Professor of Cellular Physiology at the University of Sydney and the
Academic Director of the Centre for Obesity, Diabetes and Cardiovascular Disease.

He
develop
s

the academic vision and strategy for th
e

C
entre.



He is a leading epithelial transport physiologist who has an extensive research track
record in investigating cellular mechanisms that regulate ion channels in the kidney,
gut, lung and exocrine glands
in

normal and disease states.

The significance of his
research has been recognised by
his
election to the Australian Academy of Science.

He is currently
Deputy Dean

of the Faculty of Medicine.


Professor Cook is committed to building on the University of Sydney’s strong academic and research
credentials by b
ringing together this unique research collaboration across all disciplines of the University.



SPEAKERS

Professor Stefan Blankenbe
r
g, Director, University Heart Centre, University Medical Centre,
Hamburg


Stefan

is Professor of Medicine. After studying medicine in Mainz, Frankfurt and
New York, Stefan received his MD thesis in 1998. In September 2005, he was
nominated as full Professor of medicine and became a faculty member of the
Johannes Gutenberg University,

Mainz.

Stefan has received numerous awards and prizes from institutions such as the
German Society of Cardiology, the German Heart Foundation, the European
Society of Cardiology and the Johannes
-
Gutenberg University, Mainz.

He is a member of German Socie
ty of Cardiology and the German Society of Inner
Medicine, speaker of the Work Group “Clinical Epidemiology” of the German
Society of Cardiology, member of several international committees, steering
committee member of the MORGAM (MOnica Risk, Genetics, Ar
chiving and
Monograph) study, the LIPID Study and the Gutenberg Heart Study.

Stefan has been appointed Director at the University Heart Centre of the University Medical Centre, Hamburg
as of April 2011.


Biomarkers Workshop


4


Associate/Professor Peter Meikle, Baker IDI Heart
and Diabetes Institute

Peter is Head of the Metabolomics Laboratory at Baker IDI Heart and Diabetes
Institute, and a NHMRC Senior Research Fellow.
He holds affiliate positions at Bio21
Institute (a research centre specialising in medical, agricultural and

environmental
biotechnology, The University of Melbourne and the Department of Medicine,
Monash University
)
.

The Metabolomics Laboratory has a focus on the dyslipidemia associated with
obesity, diabetes and cardiovascular disease and its relationship to

the pathogenesis
of these disease states. The work is leading to new approaches to early diagnosis, risk
assessment and therapeutic monitoring of these most prevalent diseases




Profess
or Susan Clark, Garvan Institute of Medical Research

Susan heads the epigenetic
s research group at the Garvan Institute of Medical
Research in Sydney. She graduated in 1982 with a PhD in Biochemistry at the
University of Adelaide and then spent 10 years in the Biotechnology Industry
before returning to basi
c research in gene regulation in 1992. She has a highly
acclaimed international reputation

for h
er work in mammalian epigenetic
s.


Her studies over the last 18 years have initiated profound questions about the
importance of epigenetic in early development

and disease, especially in cancer.
She has made extensive ground
-
breaking discoveries relating to DNA
methylation patterns in normal and cancer genomes that have led to tests for
early cancer detection.


The techniques she pioneered in the early 1990s in
cluding bisulphite sequencing have revolutionized and now
underpin a new era in epigenetic research.


She has a number of awards including the RPAH Research Medal in 2002, Julian Wells Medal in 2003, Ruby
Payne
-
Scott Award for contribution of women in sci
ence in Australia: “Biochemisch Analytik Preis” for
outstanding contribution for methylation analysis in 2004.


In 2006 she was elected a Fellow of the World of Technology Network for Biotechnology and in 2009 was
awarded one of Australia’s “top ten” Nati
onal Health and Medical Research Project Scientists.






Biomarkers Workshop


5


Professor Rudi Grimm
, Agilent Technologies

Rudi started his interest in glycan analysis during his time as Head of the Biotech
Laboratories of Hexal Biotech in 1999.


He and his team successfully developed the first approved biosimilar version of
EPO. Facing the analytical challenges of complex glycan mixtures during that time,
he pushed for the development of novel high
-
resolution glycan analytical tools
when he joined

Agilent Technologies in 2002, all based on Agilent’s unique HPLC
-
Chip/MS technologies. Several different glycan chips have been developed in the
meantime covering all different classes of glycan. He also initiated several
collaborations with leading glyco
mics groups in the US, Europe, Asia and
Australia.


His ongoing interest is in further development of those analytical tools as well as in novel research areas such
as paleoglycomics.



Karlheinz Peter, Baker

IDI

Heart
and Diabetes
Research Institute


Karlheinz works as an interventional cardiologist at the Alfred Hospital and as a basic
scientist at the Baker IDI Heart and Diabetes Institute. He holds an ARC Future
fellowship and an Honorary NHMRC fellowship.


Karlheinz ob
tained his MD and PhD at the

University of Freiburg, Germany, where he
also spent several years as interventional cardiologist, including as the head of the
cardiac catheter laboratory. He worked as post doctoral research officer at the Johns
Hopkins University, Baltimore and at the
Scripps Research Founda
tion, La Jolla, USA.

Most of his clinical training was done at the University of Heidel
berg, Germany.


His research is focused on the cellular mechanisms of coro
nary artery disease, encompassing the role of
platelets, coagulati
on and inflam
mation in atherosclerosis, as well as the mechanisms leading to the rupture of
atherosclerotic plaques. He has developed novel proteomic approaches and molecular imaging strategies
towards the localisation of vulnerable, rupture
-
prone plaques

and the identification of patients at risk of
myocardial infarction.








Biomarkers Workshop


6


Associate Professor Sturt Cordwell, School of Molecular Bioscience, The University of
Sydney

Stuart

is a graduate of the University of Sydney and was awarded his PhD is 1997. He

was an author on the original manuscript that defined the term ‘proteome’ in 1995
and has been involved in proteomics research throughout his career.


He was Senior Research Fellow at the Australian Proteome Analysis Facility from
1999
-
2003 and Director
of Research and Development from 2003
-
2004. He is now co
-
appointed as an Associate Professor in the School of
Molecular
Bioscience and the
Discipline of Pathology, School of Medical Science. He is a co
-
Director of the Sydney
University Proteome Research Un
it.


He was awarded the Selby Research Award in 2006 for work on bacterial membrane
proteins and a $50,000 Danish VELUX Professorship (2009) for his work on post
-
translation modification of
proteins in the heart. He was also Honorary Professor of Proteomic
s at Yonsei University in South Korea (2001
-
2004). He has generated over $3 million in competitive research funding from the ARC and NHMRC since 2006.


Stuart is a member on the Editorial Boards for
Proteomics

and
Proteomics (Clinical Application).
He has served
as the Secretary of the Australasian Proteomics Symposium since 2004 and as a member of the organising
committee for the Lorne Proteomics Symposium since 2004. He has been an invited speaker at several Human
Proteome Organisation Congresses.
He has served on several international grant review panels, including the
National Science Foundation (Washington, USA), Expert Panel Member (2001
-
2004, 2006) and an NHMRC GAG
member. He has co
-
supervised 12 PhD students and more than 20 Honours students.
In 2005, he established
the first undergraduate proteomics course in Australia.



Ian Kerridge, Values, Ethics, and the Law in Medicine, School of Public Health, The
University of Sydney


Ian
is Director and Associate Professor in Bioethics at the Centre for Values, Ethics
and the Law in Medicine at the University of Sydney and Staff
Haematologist/Bone Marrow Transplant physician at Royal North Shore Hospital,
Sydney. He is the author of over
130 papers in peer
-
reviewed journals and five
textbooks of ethics, most recently
Ethics and Law for the Health Professions

(Federation Press, 2009)
.

He is Chair of the Australian Bone Marrow Donor
Registry Research Committee and a member of the NSW Health
Department’s
Clinical Ethics Advisory Panel.


In 2005 Ian was a member of the Legislation Review Committee (Lockhart
Committee) which reviewed the
Prohibition of Human Cloning Act 2002
and the

Research Involving Human Embryos Act 2002
. His current researc
h interests in
ethics include the philosophy of medicine, stem cells, end
-
of
-
life care, synthetic genomics, public health and
organ donation.



Biomarkers Workshop


7



Clinical Associate Professor David Sullivan, Department of Biochemistry, Royal Prince Alfred
Hospital, Sydn
ey

David is a physician and chemical pathologist in the Department of Biochemistry at
RPAH and Associate Professor, Faculty of Medicine at the University of Sydney.


His previous clinical posts have included the MRC Lipoprotein Unit, Royal Postgraduate
S
chool of Medicine, Hammersmith Hospital, London and co
-
ordination of international
clinical studies from the World Health Organisation reference lipid laboratory in
Wageningen, Netherlands.


David has a long
-
term interest in lipid metabolism with particul
ar emphasis on the
dietary
component of gene


environment interactions contributing to cardiovascular
disease. He has been involved in the early use of many forms of lipid
-
lowering
interventions and his other main interest is the improvement of detection
and management of severe
inherited dyslipidaemia. David has served on numerous clinical committees including the management
committees of the LIPID and FIELD trials. He is the past President of the Atherosclerosis and Clinical Nutrition
Societies.



Associate
Professor Alicia Jenkins, Department of Medicine, The University of Melbourne


Alicia is an Associate Professor in the Department of Medicine, University of
Melbourne and undertakes clinical work in the Diabetes Clinics at St Vincent’s
Hospital
and the Royal Children’s Hospital (Melbourne). She previously headed a
Lipid and Vascular Disease Risk Factor Clinic.


Alicia graduated from medicine at the University of Melbourne in 1983. She
undertook endocrinology train
ing in Melbourne and in Ireland,
including an MD
related to lipoproteins in diabetes (University of Melbourne)
.


She spent seven years (1993
-
199
9
) in full
-
time clinical and laboratory related
research in the USA and is involved in collaborative studies related to DCCT/EDIC, VA
Diabetes Tr
ial, FIELD Trial, PROGRESS, FAMAS, and TIPS cohorts.


Her group’s research interests relate to the prediction, prevention and underlying mechanism of the vascular
complications of diabetes and of cardiovascular disease. Her research has been funded by National Institutes
of Health,
American Dietetic Associati
on,

Juvenile Diabetes Research Foundation, the Australi
an N
ational Heart
Foundation

and NHMRC.







Biomarkers Workshop


8



Professor Claire
Wade
, Chair of Computational Biology and Animal Genetics, Faculty of
Veterinary Science, The University of Sydney


C
laire is
a key player in the sequencing projects for several organisms and in
particular mammals including the opossum but also mouse, dog, sheep and horse
and the leader of one project (Horse). Claire has developed new genomics resources
that have enabled genetic
and population genetics analyses to occur for the first
time in these species. With these tools conducting sophisticated computational
genomic analysis have led to changes in the way
genomic structure is thought of

and
in some cases what might be the best
method to use to map genes more effectively.


She has held several positions nationally and internationally, in particular, Senior
Research Scientist at Massachusetts General Hospital and at Broad Institute and
Computational Biologist at Whitehead Institu
te and Broad Institute of Harvard and
MIT.

She has been the
recipient of many honors, awards and grant support. She has published in a variety of
journals such as
Animal Genetics, Genetics, Brief Functional Genomics, Science
, Genomics, Natural Genetics
an
d

Nature
.



Professor Roland Stocker
,
Discipline of Pathology, School of Medical Sciences
,
The
University of Sydney


Roland is a NHMRC Senior Principal Research Fellow. He received his training as a
biochemist at the ETH Zurich (Switzerland), A
ustralian
N
ational
U
niversity

(Canberra,
Australia) and the University of California (Berkley, USA). Following an appointment as
Assistant Professor at the University of Berne (Switzerland), Roland moved
permanently to Austra
lia in 1988 where he worked as G
roup Leade
r at the Heart
Research Institute for 13 years, as a Professor at the Centre for Vascular Research at
the University of New South Wales for five years, before taking up a Professorial Chair
at the University of Sydney in late 2006.


Roland is an internatio
nal leader in the field of redox biology who through his career
has made seminal contributions and shifted paradigms in the field of oxidative
processes and antioxidants in cardiovascular disease. His research includes the
discovery of beneficial antioxida
nt activities of the bile pigment bilirubin; identification of the reduced form of
co
-
enzyme
Q
10

as an important antioxidant in circulating lipoproteins; key discoveries understanding the
molecular action of vitamin E during lipoprotein oxidation and delin
eating contributions of the latter to
atherogenesis; pioneering work in heme oxygenase
-
1 and indoleamine 2,3
-
dioxygenase.





Biomarkers Workshop


9


Pro
fessor Anthony Keech, Deputy Director, NHMRC Clinical Trial
s Centre, Faculty of
Medicine, T
he University of Sydney


Tony

is Deputy Director of the NHMRC Clinical Trials Centre (CTC), which he joined in
1992 after time working in epidemiology at London University, followed by more than
five years at the Clinical Trials Research Unit and Department of Cardiology at Oxford
Uni
versity, UK. Anthony is jointly leading extensive biomarker and genetic work in
diabetes and cardiovascular disease based on the FIELD study cohort.


He holds an NHMRC Principal Research Fellowship, and is Professor of Medicine,
Cardiology and Epidemiolog
y in the Department of
M
edici
ne at the University of
Sydney and a practicing Consultant Cardiologist at the Royal Prince Alfred Hospital in
Sydney.


His specialist areas are treatment strategies for acute coronary syndromes, risk factor
reduction in corona
ry heart disease, and the non
-
invasive prediction of vascular disease. He has long standing
interest in lipids and heart disease, and has been a principal investigator in the Heart Protection Study, the
LIPID Trial and the FIELD Trial.


He is immediate pas
t Chairman of the Australian and New Zealand Cardiac Society Clinical Trials Working
Grou
p, and

member of many national and international committees, including multinational trial steering
committees.


Tony

has published widely in most of the leading medic
al journals.



Associate
Professor Graham Hillis, Director, Cardiovascular Division, George Institute for
Global Health


Graham Hillis is Director of the Cardiovascular Division at the George Institute for
Global Health, Senior Staff Cardiologist at Conc
ord Hospital, Sydney and Associate
Professor of Medicine at the University of Sydney.


He trained in cardiology in Edinburgh, Philadelphia and Rochester, Minnesota. From
2002 to 2008 he was Senior Lecturer in Cardiology and Consultant Cardiologist at the
University of Aberdeen and Aberdeen Royal Infirmary in the UK.


His main research and clinical interests are in general adult cardiology, the acute
coronary syndromes and coronary heart disease, peri
-
operative cardiovascular risk,
echocardiography and car
diac biomarkers.





Biomarkers Workshop


10


P
rofessor David Handelsman, ANZAC Research Institute

David is inaugural Professor/Director of ANZAC Research Institute (1998
-

). He
is Australia’s first Professor of Andrology (university of Sydney, 1996
-

) and
Head of the first
Andrology Department (Concord Hospital, 1999
-

).


After training in medicine (FRACP, Endocrinology) and research (NHMRC &
Wellcome Research Fellow), he has worked in USA and Germany and has
served numerous research and health policy bodies.


He was awarde
d the RACP’s Susman Prize (1994), the inaugural AMA Men’s
Health Award (2003) and Honorary Life Member, Endocrine Society of Australia
(2008). In 2011 he was appointed to the World
-
Anti
-
Doping Agency Health
Medicine and Research Committee.


Over 30 years,

he has published nearly 400 scientific contribution (papers cited over 8500 times, h
-
index 51)
and served 12 Editorial Boards (current Associate Editor for Male Reproduction, JCEM) and has been peer
reviewer for over 100 scientific journals, supervised or

co
-
supervised 21 PhD students and 11 other graduate
students while maintaining continuous peer
-
reviewed and industry grant funding.


His expertise in male reproductive health, medicine and biology has involved research into basic clinical,
translation an
d public health domains centred on the physiology, pharmacology and toxicology of androgens.


Professor Leonard Krithar
ides, Concord Clinical School, T
he University of Sydney

Len is Head of Departmen
t

and Director of Cardiology at Concord Repatriation Ge
neral
Hospital, Sydney where he practices as a General and Interventional Cardiologist.
He is
conjoint Professor in Medicine at the University of New South Wales (UNSW) and co
-
leader of the Macrophage Biology Group at the Centre for Vascular Research at
UN
SW.


He is the current Chairman of the Scientific Committee of the Cardiac Society of
Australia and New Zealand.


He has diverse research interests in biochemical, cellular and clinical aspects of
cardiovascular disease, including the cellular transport a
nd glycosylation of
apolipoprotein E, cellular cholesterol metabolism, and platelet and leucocytes activation in coronary disease.


His research is supported by program and project grant funding from the National Health and Medical
Research Council of Aus
tralia and Grants
-
in
-
Aid from the National Heart Foundation of Australia.